Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - UBS initiated coverage on WeRide Inc (NASDAQ:WRD) with a Buy rating and a $12.00 price target on Monday, representing roughly 37% upside from the current price of $8.74. According to InvestingPro data, analyst targets for the $2.46 billion market cap company range from $13.03 to $21.08.
The investment bank cited WeRide’s diversified product offering, which includes L2-L4 robotaxis, robobuses, robosweepers, and robovans, as key factors in its positive outlook for the autonomous vehicle technology company.
UBS highlighted that WeRide has already deployed L4 vehicles across 30 cities in 10 countries and has begun operations of L4 robotaxis in Beijing, Guangzhou, and Shanghai.
The firm expressed approval of WeRide’s "pragmatic overseas strategy" and what it described as "top-tier robotaxi technology" in its research note.
UBS projects WeRide will achieve a revenue compound annual growth rate (CAGR) of 71% from 2025 to 2030.
In other recent news, WeRide reported its second-quarter 2025 earnings, showing a substantial increase in revenue. Despite the net loss, the company’s expansion efforts and innovations in autonomous driving technology have positioned it as a significant player in the industry. UBS initiated coverage on WeRide with a Buy rating and a $12.00 price target. The firm highlighted WeRide’s diversified product offerings, which include L2-L4 robotaxis, robobuses, robosweepers, and robovans, as a key factor for its positive outlook. These recent developments indicate a strategic focus on broadening its product range and enhancing its technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.